Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) closed December 28 at $151.17, down -9.94% or $16.68 from its record high price of $167.85. Looking at the other side of the coin, VRTX traded as low as $73.23 in the past 52 weeks, and since then the shares have risen 106.43% or $77.94. The recent price momentum makes it one stock to watch in recent days. Its -0.25% depreciation from Wednesday’s close has set alarm bells ringing.
Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Performing Well?
Vertex Pharmaceuticals Incorporated (VRTX) shares are up 4.17% for the week and that has got investors and traders sitting up and taking note. VRTX is already driving a 102.67% rally over the course of the past year and is now up 105.2% since this point in 2017. Speaking of monthly performance, VRTX tapped a 2.61% gain. Also, the equity price jumped 1.04% % in three months, taking the six-month increase to 18.81% as of recent close. With that said, researchers took a deep dive into the hotly debated question: is it too late to buy Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Vertex Pharmaceuticals Incorporated (VRTX) Soon To Be A $45.85B Company
Analyst research firms are expressing bullish stance on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s near-term growth potential. They anticipate the VRTX stock will hit $182.71 on a short term (12 month) basis. Their average price target spell out an upbeat performance – a 21% and would give VRTX a market capitalization of nearly $45.85B.
Vertex Pharmaceuticals Incorporated Current Recommendations
Valued currently at $151.17, the vast majority of Wall Street analysts continue to say it’s worth buying. Mean recommendation is rated on a 1 to 5 scale. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. The Mean Recommendation is the average rating on a stock by the analyst community.
Is VRTX Technically Strong Enough?
Right now, VRTX’s beta is 1.59. That makes it 0.59 more volatile than the broad market. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is 10.64% above its 200-day moving average, providing a measure of resistance for long positions. On a similar note, the stock is 3.02% above its 50-day moving average, providing a measure of support for short positions. The average daily volatility for the week was at 2.27%, which was -0.3 lower than that in the past month.
Vertex Pharmaceuticals Incorporated (VRTX) In Neutral Territory
From another technical standpoint, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s 14-day Relative Strength Index (RSI) has reached 61.52, putting it inside a neutral zone. If the RSI is traveling up and it is between 40 and 80, it is probably an indication of an uptrend. If it moves beyond 70 but cannot hold this ground and instead falls below 70, it could be an indication that the market is overbought and prone to become bearish, at least in the short term. Conversely, if the RSI is traveling down and it is between 60 and 20, it is probably an indication of a downtrend. If it moves below 30 and fails to remain below, it could be an indication that the market is oversold and poised to become bullish, at least in the short term.
How Active Are Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares?
Technical analysts also use volume to predict trends. The current trading volume of 0.96 sits 59.38% lower than the past 3 month’s readings, indicating near-term traders have been less active toward VRTX than usual of late. The company trades on average around 153000 shares per market session. Major moves in volume can signal unusual activity, such as insider trading. Unusual volume can be a major signal that investment gurus and momentum traders are piling into a stock ahead of a catalyst. These types of traders like to get in well ahead of a large spike, so it’s always a smart move to monitor unusual volume. In terms of relative volume, these shares are trading at 1.59x their normal volume.